CRISPR screening, whether using knockout, activation, or inhibition approaches, have become essential tools for drug discovery. However, finding potential therapeutic interactions that cause cell death in the presence of a given drug can be challenging. A powerful adaptation of CRISPR screening is provided by the coupling of pooled NGS-linked or arrayed screening strategies to phenotypic measurements. By using an advanced combination of techniques, the screening strategy can be targeted to detect genes which drive complex biological responses by a biomarker signal readout or a combination of high content parameters. Horizon scientists have developed both FACS-linked and HCA-based strategies for analysis where cellular pathophysiology is uncoupled from cell health; providing much richer and biologically relevant outcomes. In this webinar we will discuss data obtained and strategies learned from several successful screens and present ongoing work using increasingly relevant cell models, such as T-cells and using single cell RNAseq-based screening approaches.

The webinar covered:

  • Discussion of the strengths and considerations associated with complex phenotypic screens
  • Examples of successful applications of pooled and arrayed phenotypic screens


Dr. Benedict Cross (Head of Functional Genomics at Horizon Discovery)
Dr. Carlos le Sage (Team Leader at Horizon Discovery)
Dr. Steffen Lawo (Team Leader at Horizon Discovery).